Department of cardiac surgery, Carmel Medical Center, 3436212, Haifa, Israel.
Sackler School of Medicine New York State/American Program, Tel Aviv University, Tel Aviv, Israel.
J Cardiothorac Surg. 2021 Jul 9;16(1):195. doi: 10.1186/s13019-021-01575-y.
Intraoperative graft assessment with tools like Transit Time Flow Measurement (TTFM) is imperative for quality control in coronary surgery. We investigated the variation of TTFM parameters before and after protamine administration to identify new benchmark parameters for graft quality assessment.
The database of the REQUEST ("REgistry for QUality AssESsmenT with Ultrasound Imaging and TTFM in Cardiac Bypass Surgery") study was retrospectively reviewed. A per graft analysis was performed. Only single grafts (i.e., no sequential nor composite grafts) where both pre- and post-protamine TTFM values were recorded with an acoustical coupling index > 30% were included. Grafts with incomplete data and mixed grafts (arterio-venous) were excluded. A second analysis was performed including single grafts only in the same MAP range pre- and post- protamine administration.
After adjusting for MAP, we found a small increase in MGF (29 mL/min to 30 mL/min, p = 0.009) and decrease in PI (2.3 to 2.2, p < 0.001) were observed after the administration of protamine. These changes were especially notable for venous conduits and for CABG procedures performed on-pump.
The small changes in TTFM parameters observed before and after protamine administration seem to be clinically irrelevant, despite being statistically significant in aggregate. Our data do not support a need to perform TTFM measurements both before and after protamine administration. A single TTFM measurement taken either before or after protamine may suffice to achieve reliable data on each graft's performance. Depending on the specific clinical situation and intraoperative changes, more measurements may be informative.
Clinical Trials Number: NCT02385344 , registered February 17th, 2015.
术中使用 Transit Time Flow Measurement(TTFM)等工具评估移植物对于冠状动脉手术的质量控制至关重要。我们研究了鱼精蛋白给药前后 TTFM 参数的变化,以确定新的移植物质量评估基准参数。
回顾性分析 REQUEST(超声成像和 TTFM 在心脏旁路手术中的质量评估登记研究)数据库。对每根移植物进行分析。仅纳入既存在术前又存在术后 TTFM 值(声学耦合指数>30%)且数据完整的单根移植物(即无序或复合移植物)。排除存在混合移植物(动静吻合)和数据不完整的移植物。随后进行第二次分析,仅纳入同一 MAP 范围的单根移植物。
调整 MAP 后,我们发现鱼精蛋白给药后,MGF(29ml/min 至 30ml/min,p=0.009)略有增加,PI(2.3 至 2.2,p<0.001)略有下降。这些变化在静脉移植物和体外循环下 CABG 手术中更为明显。
尽管在总体上具有统计学意义,但鱼精蛋白给药前后 TTFM 参数的微小变化似乎在临床上无足轻重。我们的数据不支持在鱼精蛋白给药前后均进行 TTFM 测量的需求。在给药前后进行单次 TTFM 测量可能足以获得每根移植物性能的可靠数据。根据特定的临床情况和术中变化,可能需要更多的测量才有参考价值。
临床试验编号:NCT02385344,于 2015 年 2 月 17 日注册。